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ABSTRACT (WORD LIMIT: 250 WORDS; CURRENT WORD COUNT: 250) 
Background and Aims: Chronic constipation is a serious medical condition that 
affects 30–40% of people over 60 years old. Although not normally life-threatening, 
constipation reduces quality of life by the same extent as diabetes and osteoarthritis. 
There are currently no Europe-wide guidelines for treating constipation in older 
people although there is some country-level guidance for the general population. We 
have evaluated the existing guidance and best clinical practice in order to improve the 
care of older people with constipation. 
Method: European healthcare professionals working in gastroenterology, geriatrics, 
nursing and pharmacology discussed the treatment of constipation in older people and 
reviewed existing guidance on the treatment of constipation in the general population. 
This manuscript represents the consensus of all authors.  
Discussion: Most general guidance for constipation treatment recommends increased 
dietary fibre, fluid intake and exercise; however, this is not always possible in older 
patients. Although a common first-line treatment, bulk-forming laxatives are 
unsuitable for older people because of an associated need to increase fluid intake. 
Osmotic laxatives are likely to be the most suitable laxative type for older patients. 
Treatment is often hampered by reluctance to talk about bowel problems so healthcare 
providers should proactively identify older constipated patients who are self-
medicating or not receiving treatment. 
Conclusions: With certain modifications, general treatment guidelines can be applied 
to older people with constipation although specific guidelines are still required for this 
age group. Awareness of constipation, its complications and treatment options needs 
to be increased among healthcare providers, patients and carers. 
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What’s Known? 
Chronic constipation is a disorder that disproportionately affects older people; 
however, no clear pathophysiological reason for this has been identified. Untreated 
constipation can eventually lead to inpatient hospitalisation and increases the risk of 
impaction and faecal incontinence. Despite its high prevalence in older people, there 
are no treatment guidelines specific to this population at a national or European level. 
What’s New? 
A panel of experienced healthcare professionals used their clinical expertise to 
evaluate the existing treatment guidelines for constipation and apply them to the 
treatment of constipation in older people. Based on existing guidance and their own 
clinical experience, the panel also proposed methods that will allow healthcare 
providers to identify patients with untreated constipation and enable treatment before 
they require admission to secondary care.  
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INTRODUCTION 
Background 
The median prevalence of constipation is estimated to be 16% in adults overall and 
33.5% in those aged 60–101 years [Bharucha et al., 2013a]. However, despite its high 
prevalence, the precise symptoms of constipation are ill-defined [Chatoor et al., 
2009]. In general, patients are reported to associate constipation with both infrequent 
bowel movements and stools that are difficult to pass; on the other hand, physicians 
have been found to prioritise stool frequency when diagnosing constipation [Herz et 
al., 1996]. It was these generally contrasting views that led to the development of the 
Rome Diagnostic criteria, which have become the most widely used clinical definition 
of constipation [Longsreth et al., 2006; Lacy et al., 2016]. 
Although constipation is not normally life threatening, it is known that its impact on 
the quality of life of those suffering with the condition can be as great as the impact of 
diabetes and osteoarthritis [Belsey et al., 2010]. Older patients with constipation are 
also at risk of psychological and social distress. The seriousness of constipation 
combined with its high prevalence has the potential to place a considerable burden on 
healthcare infrastructure; for example, in England between April 2013 and April 
2014, there were 63,427 patients admitted to hospital with constipation and this 
accounted for 159,997 bed days [Health and Social Care Information Centre, 2015a]. 
Given that the average cost of a single bed day (excluding the cost of treatments and 
procedures) is £303 (~€375) to the UK National Health Service [Department of 
Health (UK), 2015] there is an undeniable economic case for identifying and treating 
constipated patients before they require hospital admission. Unfortunately, equivalent 
economic data for other European countries are not publicly available although a 
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recent comparative survey suggests that the prevalence of constipation is similar in 
France, Germany, Italy and the UK [Wald et al., 2008]. 
Chronic constipation is a particular problem in older people. It is estimated to affect 
30–40% of older people living at home and over 50% of nursing home residents 
[Gallagher et al., 2009]. However, it is believed that the increased prevalence of 
constipation in older people is not due to age-related physiological changes; a healthy 
older person is as likely to experience constipation as a young person is [Norton, 
2006; Gandell et al., 2013]. Reduced physical activity is thought to be a major cause 
of constipation in older people with active individuals being less likely to experience 
constipation than those who are chair-bound who are themselves less likely to 
experience it than the bed-bound [Kinnunen, 1991]. Similarly, constipation is more 
common in older people who are resident in long-stay wards than those who live in 
the community [Read et al., 1995] and has a prevalence of around 70% in this 
population [Rey et al., 2014]. It has been observed that being bedridden for over 
15 days is significantly associated with dissatisfaction with bowel emptying 
movements [Cardin et al., 2010]. Another key cause of constipation, which is 
particularly relevant to older people, is the impact that polypharmacy has on the 
function of the gastrointestinal tract [Dennison et al., 2005]. Unfortunately, it may not 
be possible to reduce the number of medications an older person receives nor is it 
always possible to increase their levels of physical activity; this highlights the 
importance of effective pharmaceutical intervention to treat constipation in older 
people. 
If constipation is not treated effectively, it can develop into faecal impaction 
[Gallagher et al., 2008], which can often require emergency hospitalisation. In 
England in 2014, 792 patients aged 60 years and over were admitted to hospital for 
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manual evacuation of impacted faeces; this age group represented 68% of all adult 
admissions for this procedure [Health and Social Care Information Centre, 2015b]. 
The average length of hospital stay for a patient with impaction was 7 days – a burden 
on healthcare resources that could easily be avoided through better management of 
constipation. Furthermore, uncontrolled constipation is the main risk factor associated 
with cases of faecal impaction in nursing homes [Rey et al., 2014]. 
However, appropriate management requires timely recognition of the symptoms and 
this can be complicated by the apparently contradictory connection between 
impaction and incontinence [Nelson et al., 1998]. For example, it has been shown that 
by ensuring complete rectal emptying it was possible to reduce the frequency of 
faecal incontinence in a group of elderly nursing home residents [Chassagne et al., 
2000]. These findings appear to demonstrate that effective, early treatment of 
constipation can have a beneficial effect on the quality of life of frail patients. Bowel 
health is also related to overall health; for example, faecal impaction may be 
associated with urinary dysfunction and can lead to stercoral ulceration and bleeding 
[Gallagher et al., 2009; Serrano Falcón et al., 2016]. An additional risk of impaction is 
that it can cause faecal overflow that can be mistaken for incontinence; if this is 
treated with an anti-diarrhoeal it can make the impaction worse [Tracey, 2000; De 
Lillo et al., 2000]. Improperly diagnosed ‘overflow’ incontinence resulting from 
impaction can also be a key trigger of nursing home admission [Wilson, 2005; 
Norton, 2006]. The potential for confounded diagnosis that results in inappropriate 
treatment and subsequent failure of the condition to respond (or even get worse) only 
serves to underline the importance of identifying and treating chronic constipation in 
older people. 
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The Need for a Consensus Statement 
Although several organisations have produced treatment guidelines that address 
chronic constipation in the general population [Paré et al., 2007; Piche et al., 2007; 
Bergert et al., 2010; Nederlands Huisartsen Genootschap, 2010; Bove et al., 2012; 
Andresen et al., 2013; Bharucha et al., 2013b; National Institute for Health and 
Clinical Excellence, 2015; Serra et al., 2016], there are no guidelines that specifically 
describe how to manage the condition in older people [International Longevity 
Centre-UK, 2013]. It was recognised by the consensus panel that the lack of clear 
advice on the best way to manage constipation in older people is a serious oversight, 
particularly in light of how frequently it occurs in this population and its potential to 
markedly impact on patient quality of life. To address the lack of guidance, this 
consensus statement was developed to evaluate the existing guidelines with respect to 
the unique challenges that the older population faces. 
It was also recognised that there is an urgent need to increase awareness of 
constipation. Patients and health care providers alike need to know the importance of 
early treatment and the serious risk of complications; therefore, this consensus 
statement considers current approaches towards constipation treatment and proposes 
several methods that could be adopted to improve patient quality of life and reduce 
the economic burden of constipation. 
METHODS 
A meeting was arranged to discuss constipation in older people. European healthcare 
professionals were invited and a date was chosen such that the greatest number of 
responders could attend. A panel of six of these experts met in London in October 
2015. The panel represented five European countries (Germany, Italy, the 
8 
 
Netherlands, Spain and the United Kingdom) and came from a variety of backgrounds 
(gastroenterology, nursing, geriatrics and pharmacology). Each member of the panel 
had significant clinical experience of treating older people with constipation. Several 
panel members also had a background in clinical research and guidance development. 
Before the meeting, attendees voted to determine the priority of discussion topics and 
an agenda was created. At the meeting, participants discussed, in structured form, 
their understanding of how constipation is addressed in their own country, their own 
experience of treating constipation and ways they thought that treatment could be 
improved. The day’s discussion was summarised in a comprehensive set of minutes 
and these were used to compile a list of consensus points, which were approved by the 
meeting participants. The group also provided their most relevant local treatment 
guidelines and these were evaluated along with guidelines from countries not 
represented in the meeting. This local guidance was supplemented with the group’s 
consensus on best practice advice based on literature and experience. The minutes, 
consensus points and treatment guidance were then used to prepare this manuscript. 
All panel members were involved in the writing, review and approval of the 
manuscript. 
DISCUSSION 
Constipation is a serious problem for older people 
There is a widely held belief among the public that constipation is related to lifestyle 
factors such as poor diet and lack of exercise [Mihaylov et al., 2008]. As a result, the 
majority of people experiencing constipation will respond by changing their lifestyle 
as opposed to seeking pharmaceutical treatments [Wald et al., 2008]. However, there 
is limited evidence to suggest that lifestyle factors are always the main cause of 
constipation and that changing one’s behaviour will alleviate constipation [Müller-
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Lissner et al., 2004]. Increased fibre consumption is often recommended as a 
treatment for constipation and, though it is sometimes effective, there are situations 
where it can make constipation worse and/or cause additional discomfort to patients 
due to bloating, flatulence and distension [Read et al., 1995; Bosshard et al., 2004; 
Müller-Lissner et al., 2005]. Reduced mobility is also implicated as a cause of 
constipation although research suggests that it is often only one of several factors and 
that increasing mobility alone will not provide relief from constipation [Müller-
Lissner et al., 2005]. Importantly, low mobility in older people may be the result of 
frailty and it may not be possible for them to exercise. 
Review of Existing Guidance 
Although there are no formal European-level guidelines for the treatment of 
constipation in older people, several countries have issued guidelines that are intended 
to provide advice for healthcare providers treating constipation in the general 
population. Much of the information from these guidelines can be applied to older 
people; however, it is important to consider the aging population in their own context. 
Below, various national guidelines are summarised with a particular emphasis on how 
the information pertains to older patients. 
United Kingdom 
The UK’s National Institute for Health and Clinical Excellence (a public body that 
develops clinical guidelines) has issued separate clinical recommendations for the 
treatment of constipation in adults and children but no guidelines have yet been issued 
for older people [National Institute for Health and Clinical Excellence, 2015]. In the 
guidelines addressing constipation in adults, healthcare providers are recommended to 
inform patients of the importance or dietary fibre, fluid intake and exercise and to 
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identify any medication that the patient may be taking that could cause constipation. 
Patients should be reminded that defecation should be unhurried and that they should 
attempt to defecate soon after waking or within 30 minutes of a meal. Particularly 
relevant to older patients is the recommendation that people with limited mobility 
should have sufficient access to carers such that they can quickly respond to the urge 
to defecate. 
Once it is established that lifestyle factors are not responsible for a patient’s 
constipation, the recommended first-choice laxative is a bulk-forming laxative; 
however, the guideline specifically notes that the necessary increase in fluid intake 
might make this unsuitable for older people. Osmotic laxatives are the recommended 
alternative to bulk-forming laxative with macrogol preferred over lactulose. In the 
event that stools continue to be difficult to pass despite being soft, the guidelines 
advise that a stimulant laxative should be administered with the osmotic laxative.  
During the discussions that took place as part of the development of this consensus 
statement, it was noted that clinical experience in the UK suggests that sodium 
docusate is a good first-choice laxative for initial treatment of older people. In the 
event that sodium docusate is ineffective, an osmotic laxative should be used with 
macrogol as the first choice. It was also proposed that if stools are softened by 
laxative treatment but are still difficult to pass, a glycerine suppository, stimulant 
laxative or a microlax enema should be considered in that order of preference unless 
rectal administration is not acceptable for the patient or carer. 
The guidelines also describe a detailed approach for the treatment of impaction. In the 
event that the impacted stool is hard, a high, escalating dose of oral macrogol should 
be used. An oral stimulant laxative is recommended when this approach is found to be 
ineffective, or if stools were soft to begin with. If oral laxative treatment fails to 
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resolve impaction, suppositories (bisacodyl for soft stools and glycerol with or 
without bisacodyl for hard stools) or a docusate or sodium citrate enema should be 
considered. If these first-choice enemas do not succeed, sodium phosphate or arachis 
oil enemas should be used. Clinical experience in the UK has found this approach to 
be suitable for older people. 
Germany 
In Germany, a guideline on pathophysiology, diagnosis and treatment of chronic 
constipation in the general population was written based on a systematic literature 
search [Andresen et al., 2013]. Participating experts were selected by the German 
Society of Neurogastroenterology and Motility and the German Society for Digestive 
and Metabolic Diseases in cooperation with four further medical societies. 
The guideline suggests that frequently cited pathophysiological factors such as a low-
fibre diet, insufficient fluid intake and lack of mobility may aggravate existing 
constipation, but have not been proven to cause constipation; therefore, measures to 
correct such deficiencies are of unclear benefit. Nonetheless, patients should be 
advised to increase dietary fibre, aim to drink 1.5–2 L of fluid per day, maintain a 
level of exercise appropriate for their age and avoid habitual voluntary stool restraint. 
If lifestyle changes and bulk-forming laxatives like psyllium prove insufficient or 
intolerable, further medical therapy should be considered.  
The guideline recommends macrogol, bisacodyl and sodium picosulfate as first-
choice treatments. The recommended second-line treatments are anthrachinones and 
sugars/sugar alcohols (lactulose, lactitol, sorbitol and, depending on the individual 
disposition, lactose). Further possibilities are combinations of the aforementioned 
measures, suppositories (e.g., bisacodyl) and, as a temporary measure only, enemas. 
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Salinic laxatives such as magnesium hydroxide, are not recommended for chronic 
constipation due to possible adverse effects. Paraffin oil is not recommended due to 
the risk of lipid pneumonia secondary to microaspiration and disturbed absorption of 
lipid-soluble vitamins. Prucalopride is recommended for use only where lifestyle 
changes and conventional therapy have been unsatisfactory or intolerable. Where 
available, lubiprostone and linaclotide can be used to treat prucalopride-resistant 
constipation; the development of patient-specific treatment regimes is encouraged.  
Opioid-induced constipation can treated using opioid antagonists. Methylnaltrexone is 
mentioned but it has the disadvantage of requiring subcutaneous administration. 
Further antagonists are alvimopan and oral naloxone. It should be noted that since the 
guideline was published, Naloxegol, a pegylated naloxone derivative, has been 
approved. 
In addition, relevant guidelines for the treatment of constipation in a palliative care 
setting have been published by the Leitliniengruppe Hessen (Hesse Guidelines Group) 
under the auspices of Kassenärztliche Vereinigung Hessen (Hesse Association of 
Statutory Health Insurance Physicians) [Bergert et al., 2010]. Patients in palliative 
care often experience frailty, immobility, polypharmacy and decreased fibre and fluid 
intake. In many ways, this makes them comparable with older people from the point 
of view of constipation and its treatment. The guidelines recommend that the first 
stage of treatment should involve an increase in fibre, fluids and exercise. However, if 
these lifestyle changes are difficult to make because of a patient’s condition, 
therapeutic intervention is recommended. In the first instance, therapies based on 
macrogol with electrolytes are advised because they rarely cause bloating and they 
maintain electrolyte balance. In the event of a hardened stool, stimulant laxatives with 
the possible addition of lubricants should be used with manual removal considered a 
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last resort. For patients who cannot swallow, rectal administration of bisacodyl or 
glycerol is recommended.  
Italy 
The Italian Association of Hospital Gastroenterologists and the Italian Society of 
Colo-Rectal Surgery published an evidence-based consensus statement on the 
diagnosis and treatment of chronic constipation and obstructed defecation in adults 
[Bove et al., 2012]. The authors found no evidence that constipation can be effectively 
treated by increasing physical exercise and improving defecation habits; increased 
fluid intake is recommended only if a patient is dehydrated. The guideline awards the 
highest grade of recommendation (grade A) to macrogol, tegaserod and prucalopride. 
Psyllium, lactulose, lubiprostone and linaclotide receive a Grade B recommendation.  
Experience from Italy suggests that treatment of older people with constipation should 
begin with a thorough review of the patient’s medications. If any constipation-causing 
medications are identified, the aim is to replace them with alternate therapies where 
possible. If this is not possible or fails to resolve the constipation, patients who are 
consuming less than 30 g of soluble fibre per day should aim to increase their intake 
to this level gradually. In addition, patients should be educated on recognising and 
responding to the urge to defecate and, in order to benefit most from the gastrocolic 
reflex, visits to the toilet should be routinely scheduled soon after waking and after 
meals. Elevating the feet with a foot stool and, if possible, abdominal and pelvic floor 
muscle-strengthening exercises may provide additional help with defecation [Lacy et 
al., 2016]. 
It is generally considered that when patients fail to respond to fibre supplementation, 
osmotic laxatives such as macrogol should be used, with the dose titrated until a 
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clinical response is achieved. Syrup-based formulations are particularly well tolerated 
by dysphagic patients. In patients with more refractory constipation, stimulant 
laxatives (bisacodyl, senna) and prokinetic agents (prucalopride 1 mg/day) or 
secretagogue drugs (such as linaclotide, which improves intestinal transit and 
abdominal pain) should be used, if necessary in conjunction with osmotic laxatives. In 
patients with pelvic floor dysfunction, periodic hydrocolontherapy or once- or twice-
weekly enemas are considered effective. Where patients have no cognitive 
impairment and demonstrate ano-rectal muscular integrity, biofeedback therapy can 
be effective in patients with pelvic floor dysfunction or faecal incontinence. 
For residents of nursing homes, a daily stool diary should be maintained with a record 
of stool profile as described by the Bristol stool scale. It is important for the nurses 
who have daily contact with patients to coordinate their activities with attending 
physicians, especially in residents who are not able to report symptoms. Attention 
from a dietician may also be beneficial. Macrogol should be used as the first-line 
therapeutic intervention with dose titrated according to patient response. After three 
days without a bowel movement, a rectal exam should be conducted followed by a tap 
water enema. A combination of osmotic laxatives with stimulant or prokinetic 
laxatives (bisacodyl/senna or prucalopride) is also considered to be effective in 
nursing home residents suffering with constipation. A technical aid in the 
management of constipation that has been shown to have some effect in older people 
is an abdominal massage, which can increase the frequency of bowel movements  and 
decrease discomfort in patients with constipation (Sinclair, 2011). 
The Netherlands 
Dutch guidelines have been issued by the Nederlands Huisartsen Genootschap (Dutch 
College of General Practioners) for the treatment of constipation in the general 
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population [Nederlands Huisartsen Genootschap, 2010]. The guidelines recommend 
lactulose or macrogol as first-line treatments and note that macrogol with electrolytes 
is as effective as macrogol without electrolytes. Macrogol with electrolytes is 
recommended for treating faecal impaction. If a patient does not tolerate a treatment – 
for example, they experience bloating or dislike the taste – the health care 
professional should select another treatment. 
Spain 
Spanish guidelines for the treatment of constipation in the general population were 
developed using an evidence-based approach and released in 2016 [Serra et al., 2016]. 
The guideline recommends that after drug-related or medical causes of constipation 
have been ruled out, patients should be encouraged to increase consumption of 
soluble fibre and fluids and take regular exercise. If this is not possible or is 
ineffective, osmotic laxatives are recommended as the first line treatment with the 
guidelines noting the stronger evidence base for the use of macrogol over lactulose. 
Stimulant laxatives should be used as a recue medication for non responders. When 
laxatives fail to produce a satisfactory relief of symptoms, prucalopride is 
recommended as an alternative. A functional study by a gastroenterologist should take 
place if none of these treatments is effective. Clinical experience in Spain indicates 
that these general guidelines would be suitable for the treatment of older patients. 
France 
In France, general treatment guidelines have been issued by the Société Française de 
Gastroentérologie (French Society of Gastroenterology) [Piche et al., 2007]. The 
authors took a systematic, evidence-based approach, which considered 722 different 
articles. The guidelines recommend that the first step of any treatment should be for 
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healthcare professionals to remind patients of the importance of maintaining regular 
toilet habits and to establish that patients are allowing sufficient time for bowel 
movements and that they have enough privacy. The guidelines also cite a study in 
older people reporting that the use of a footstool while on the toilet improves stool 
movement of through the anal canal. The guidelines do not find sufficient supporting 
evidence for them to recommend increased hydration and increased physical activity. 
A gradual increase of dietary fibre intake is suggested although the guidelines 
mention that it may only have a modest impact.  
The first-line therapeutic interventions recommended by the guidelines are osmotic 
laxatives (macrogol, lactulose or milk of magnesia) and bulk-forming laxatives 
(psyllium, ispaghula, sterculia gum and bran). No single laxative is identified as a 
first-choice treatment. Stool softeners are recommended as a second-line treatment 
although the guidelines note the propensity of mineral oils to increase the risk of 
faecal incontinence and anal seepage, and the possibility that they may leech lipid-
soluble vitamins A, D, E and K. The guidelines also mention that elderly patients may 
be at risk of complications caused by choking on orally administered oils. Stimulant 
laxatives are recommended for use only when other treatment options have failed; 
however, their usefulness in especially frail elderly patients is noted. For certain older 
patients or patients with neurological diseases suppositories and enemas are proposed. 
Canada 
A Canadian consensus group was assembled to evaluate the literature and produced a 
statement on the treatment of constipation in a general population [Paré et al., 2007]. 
The group concluded that there was insufficient evidence to support increased fluid 
intake and increased exercise to relieve constipation although they supported the use 
of increased fibre intake. It is noted, however, that older patients may already have 
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especially low fluid intake and that this should be increased. Unsurprisingly, given 
that both guidelines were based on a comprehensive review of clinical trial data, the 
conclusions of the panel were similar to those of the Société Française de 
Gastroentérologie [Piche et al., 2007]. Initially, it is recommended that patients are 
educated on bowel function followed by a gradual increase in dietary fibre. Should 
this be ineffective, osmotic laxatives are recommended followed by glycerine-based 
suppositories if necessary. A specific osmotic laxative is not recommended although 
the guidelines note that milk of magnesia is cheaper than macrogol. However, the 
guidelines also highlight the gas-producing effect of lactulose and the fact that there 
have been no long-term studies of the effectiveness of lactulose or milk of magnesia. 
USA 
The American Gastroenterological Association has also published a set of guidelines 
for the treatment of constipation in the general population [Bharucha et al., 2013b]. In 
common with several other guidelines, they recommend increased fibre as the initial 
treatment. As a first line treatment, they recommend an inexpensive osmotic agent 
with milk of magnesia and macrogols given as examples. 
Summary of local guidance 
Figure 1 shows a simple treatment flowchart based on the local guidelines discussed 
above. 
Osmotic laxatives are considered to be the most effective treatment in the general 
population [Gandell et al., 2013] and this is reflected by their recommendation as a 
first-choice laxative in general treatment guidelines in Germany [Bergert et al., 2010; 
Andresen et al., 2013], Netherlands [Nederlands Huisartsen Genootschap, 2010], 
Spain [Serra et al., 2016], France [Piche et al., 2007], Canada [Paré et al., 2007] and 
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the USA [Bharucha et al., 2013b]. In contrast, the UK’s National Institute of Clinical 
Excellence guidelines recommend bulk-forming laxatives over osmotic laxatives 
although they note that the increased fluid intake required by patients receiving bulk-
forming laxatives may make them unsuitable for older people [National Institute for 
Health and Clinical Excellence, 2015]. Several clinical trials have demonstrated the 
effectiveness of osmotic laxatives in this population. For example, lactulose has been 
shown to reduce constipation-associated symptoms in older people [Wesselius-De 
Casparis et al., 1968; Sanders, 1978] and the clinical effectiveness of macrogol with 
electrolytes has been demonstrated in older people with Parkinson’s disease 
[Zangaglia et al., 2007]. 
The relative effectiveness of lactulose and macrogol in the general population was 
recently evaluated in a Cochrane review [Lee-Robichaud et al., 2010]. The review 
considered data from 10 clinical trials and concluded that, overall, macrogol increased 
stool frequency and improved stool form. As well as the clearer efficacy of macrogol 
over lactulose, there are also reports of bloating and flatulence when lactulose is 
metabolised by gut flora – something that impacts on treatment tolerability and patient 
quality of life [Attar et al., 1999]. 
Awareness of constipation 
The perception that chronic constipation is not in itself a treatable medical condition 
leads to under-reporting and this is compounded by the fact that many older people 
consider bowel health a private matter and find it difficult to discuss [Norton, 2006]. 
Consequently, many patients resort to self-medication [De Lillo et al., 2000; Dennison 
et al., 2005] and therefore do not benefit from the expertise of healthcare 
professionals. 
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In order to circumvent the self-imposed social stigma associated with constipation, the 
authors recommend that healthcare providers should proactively identify patients with 
constipation who are not receiving appropriate treatment. In older patients, this could 
be addressed by asking few short questions at routine health visits that would allow 
healthcare providers to determine if any treatment is required. The questions could be 
as simple as “are you happy with your bowels?”, “how long do you spend on the 
toilet?”, “do you ever need to strain on the toilet?”, “how frequent are your bowel 
movements?”, “do you use any medication for your bowel?”. Alternatively, questions 
that are more general could be asked such as “do you have any problems with your 
bowels?” or “do bowel symptoms prevent your enjoyment of any part of life?”. 
Introducing patients to the Bristol stool scale may also assist in the discovery of 
undiagnosed constipation. Where a healthcare provider thinks that a patient might be 
constipated, they can ask further questions and decide on an appropriate intervention.  
To encourage patients who self-medicate to seek professional advice, a partnership 
with pharmacists would be useful. For example, when a patient buys an over-the-
counter constipation treatment, the pharmacist should ask a simple question such as 
“how long have you been using this?”. If the answer is longer than 3 months, the 
pharmacist should recommend an alternative treatment or encourage the patient to 
seek further advice from a healthcare provider. 
One final group of older people with constipation who may prove difficult to identify 
are older people with communication difficulties [Tracey, 2000]. In the opinion of the 
authors, stool diaries and digital rectal examination could be used with the goal of 
identifying constipation before patients require treatment for impaction. As discussed 
above, preventing impaction is likely to reduce the occurrence of faecal incontinence; 
this is important on many levels because it can have a substantial negative impact on 
the dignity of patients and increases the workload of nursing home staff. 
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To better emphasise the need for proactive identification of patients suffering with 
constipation, the economic aspects of constipation need to be thoroughly considered. 
Only through the collection and reporting of robust patient outcome data will it be 
possible to encourage general practitioners to think in terms of long-term secondary 
care costs instead of short-term prescribing costs. To date, there has been almost no 
research into the secondary care costs of untreated constipation although a report by 
the company Coloplast determined that constipation cost UK hospitals £145 million 
(€179 million) in 2014/15 [Coloplast, 2016]. Some research has reported on the 
estimated economic value of macrogol over lactulose [Christie et al., 2002; Guest et 
al., 2008] but the research only considers the basic cost of the treatments and does not 
evaluate the cost of secondary care that can arise from complications. 
Potential benefits of the consensus statement 
The principle aim of this consensus statement was to evaluate the current guidance on 
the treatment of constipation and assess its applicability to an older population. This 
combined advice is intended to improve patient care and reduce the likelihood of 
complications such as faecal impaction. It can also be anticipated that patients who 
are successfully treated will be encouraged to seek treatment for similar problems in 
the future and will therefore have improved bowel health for their entire lives. 
The authors seek to reemphasise the serious nature of constipation and address the 
reasons it continues to go undetected and untreated. It needs to be emphasised that 
patients can be reluctant to discuss bowel problems and that it is up to healthcare 
professionals to identify proactively those patients who are unsuccessfully self-
medicating or who do not realise they have a problem. By increasing awareness of the 
personal, social and economic costs of constipation, it is envisaged that a greater 
number of constipated patients will receive the attention they need and be treated 
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appropriately. It is likely that this will reduce the number of patients requiring 
expensive secondary care. Public awareness of bowel issues needs to be increased; in 
short, people need to know that they can be happy with their bowels. They also need 
to know that acute episodes of constipation can be addressed with the help of 
healthcare professionals before the secondary consequences of untreated constipation 
impact on health and well-being. By raising these issues in this consensus statement, 
it is hoped that the relevant authorities will be encouraged to reach out to older 
patients suffering with constipation and let them know that support is available. 
CONCLUSIONS 
The bowel health of older people has the potential to have a marked impact on their 
overall quality of life; unfortunately, it is something that many people are 
uncomfortable discussing. For this reason, constipation often goes untreated, which 
increases the risk of impaction and incontinence. This consensus statement provides 
treatment guidance for older people, which is itself derived from general evidence-
based treatment guidelines that have been produced by respected national authorities. 
Furthermore, it draws attention to the social and economic importance of effective 
constipation treatment and includes suggestions for healthcare providers to identify 
patients who are unsuccessfully self-medicating or not seeking treatment. It is hoped 
that this consensus statement will serve to focus attention on the opportunity to 
improve the quality of life of patients and reduce the economic burden of constipation 
across Europe. The present document underlines the current issues and how the 
healthcare community is failing older people. The authors hope that this work will 
serve as a ‘call to arms’ to those working with older people to develop guidelines, 
especially where they do not already exist, that address the challenges posed by the 
condition.  
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Figure 1 Treatment of Constipation 
   
Advise patient on lifestyle 
measures: 
- Increase dietary fibre 
- Eat regular meals 
- Drink sufficient fluids 
- Increase mobility 
- Toileting advice (including 
correct position on toilet) 
Is the patient receiving medication 
that is known to cause constipation? 
Can the medication be 
stopped/replaced? 
Stop/replace medication 
Osmotic laxative 
Stimulant laxative 
Suppositories/enema 
If two laxatives from different 
classes have been tried at the 
highest dose without success for at 
least six months, consider 
prucalopride or lubiprostone 
NO 
Increase patient’s fluid and fibre 
intake and use an osmotic laxative 
and a stimulant laxative 
Enema  
(if continuous treatment not 
required) 
If an effective treatment is found, adjust dose as necessary and repeat 
treatment as required. Consider withdrawal if patients regularly produce 
soft, formed stools. Withdrawal should take place after 2–4 weeks of 
normal passage of stool. Withdrawl should not be sudden and may take 
several months. For drug-induced constipation, continue for as long as 
constipating drug is used. 
START 
Opioid-induced constipation 
Stop/replace medication 
Patient unable to swallow 
Rectal administration of stimulant 
laxative 
Rectal administration of stimulant 
laxative with stool softener 
Specific treatment scenarios 
Osmotic laxative administered orally 
as syrup 
Administration of osmotic laxative 
via gastrostomy tube (if present) 
Opioid antagonist (Naloxegol 
preferred if available) 
Trans-anal irrigation 
YES 
YES 
NO 
